IHS Chemical Week
CHEM IDEAS

Pharma/fine chemicals roundup—19 May 2015

May 19, 2015 | By DEEPTI RAMESH

API business of Dr. Reddy’s reports rise in sales The pharmaceutical services and active ingredients (PSAI) business of Dr. Reddy’s Laboratories (Hyderabad, India) reports a 11.6% rise in sales in the company’s fiscal fourth quarter, ended 31 March 2015, compared with the year ago quarter, to 7.41 billion Indian rupees ($117 million). For the full fiscal year ended 31 March, the PSAI...

Pharma/fine chemicals roundup—12 May 2015

May 12, 2015 | By DEEPTI RAMESH

Siegfried to buy certain pharma ingredients businesses from BASF for €270 million BASF and Siegfried (Zofingen, Switzerland) announced that Siegfried will acquire BASF’s custom synthesis business and parts of its active pharmaceutical ingredients (APIs) business, for €270 million ($306 million). These include APIs such as ephedrine, pseudoephedrine and caffeine. The transaction also...

Pharma/fine chemicals roundup—5 May 2015

May 5, 2015 | By DEEPTI RAMESH

Lonza well positioned to deliver 2015 targets Lonza, in its business update announcement for the first quarter of 2015, says that the year started with overall good momentum, leading to business performance fully in line with the company’s expectations. Lonza's specialty ingredients and the pharma and biotech segments realized growth targets and achieved good results, Lonza says. The impact of the...

Pharma/fine chemicals roundup—28 April 2015

April 28, 2015 | By DEEPTI RAMESH

FDA issues warning letter to API plant in China The US FDA issued a warning letter on 6 April to the active pharmaceutical ingredient (API) manufacturing facility of Yunnan Hande Bio-Tech—located at Kunming, China—for violating cGMP. The warning letter was published on the FDA Web site on 21 April. An FDA inspection from 14–17 April 2014 at the Kunming facility identified significant...

Pharma/fine chemicals roundup—21 April 2015

April 21, 2015 | By DEEPTI RAMESH

Indian API industry to grow 10%/year to reach $17.5 billion by 2018; government initiates several measures to support API industry The Indian active pharmaceutical ingredient (API) industry, which is currently valued at about $11 billion, is expected to grow at a CAGR of about 10% to reach $17.5 billion by 2018, Dinesh Dua, CEO and director of pharmaceutical firm Nectar Lifesciences (Chandigarh, India)...

Pharma/fine chemicals roundup—7 April 2015

April 7, 2015 | By DEEPTI RAMESH

Aptuit expands API capacity in Italy and UK Aptuit (Greenwich, CT) says that it has increased its capacity for active pharmaceutical ingredient (API) manufacture in Italy and the United Kingdom due to increased demand for APIs, and for integrated and comprehensive candidate-to- investigational new drug (IND) development solution. “Customer demand for our integrated, fully inclusive candidate-to-IND...

Pharma/fine chemicals roundup—31 March 2015

March 31, 2015 | By DEEPTI RAMESH

Sun Pharma completes acquisition of Ranbaxy Sun Pharmaceutical Industries (Mumbai) says that it has completed the previously announced acquisition of Ranbaxy Laboratories (Gurgaon, India). Sun Pharma announced in April 2014 that it would acquire Ranbaxy in an all-stock transaction valued at about $3.2 billion. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. With the...

FDA to use metrics initiative to improve drug quality throughout supply chain

March 26, 2015 | By LAWRENCE SLOAN

Combating drug quality and supply shortages are ongoing concerns for stakeholders throughout the pharmaceutical supply chain, including members of SOCMA’s Bulk Pharmaceuticals Task Force (BPTF). As a means to address these concerns, the U.S. Food and Drug Administration (FDA) is working with the pharmaceutical supply chain on a new Quality Metrics Initiative (QMI). This new initiative, which has been...

Pharma/fine chemicals roundup—24 March 2015

March 24, 2015 | By DEEPTI RAMESH

Weifa to spin off API business Weifa (Oslo), Norway's leading fully-integrated pharmaceutical company and a major supplier of active pharmaceutical ingredients (APIs), says that its board plans to separate the company’s consumer health-care and API operations through a transfer of its API business and tablet production to Vistin Pharma, a newly established subsidiary of Weifa that will be listed on...

Moving forward on white biotech

March 20, 2015 | By ALISTAIR REID AND DALE STEICHEN

Industrial biotechnology, also known as white biotech, presents some truly game changing opportunities for the manufacturing sector. In particular, it is serving as a source of raw materials and intermediates that may be cheaper, more sustainable, and offer advantages in terms of performance that were never imaginable with materials produced by more conventional ‘straight chemical’...


ABOUT CHEM IDEAS

Welcome to Chem Ideas, the place for opinions and perspective on the key issues affecting the global chemicals industry. This zone features articles by Chemweek’s regular editors as well as a team of established experts with insights across the chemicals industry. If you would like to contribute a blog or opinion piece contact rob.westervelt@ihs.com.



CLICK HERE TO LEARN ABOUT CHEMWEEK'S EDITORS











 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa